Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog

Vincent J A Bourgonje1, Marieke Schoenmakers, Jet D M Beekman

  • 1Department of Medical Physiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. v.j.a.bourgonje@umcutrecht.nl

Heart Rhythm
|August 1, 2012
PubMed
Abstract

Insights

Calcineurin is not involved in long-term cardiac remodeling in dogs. While CaMKII is chronically activated, acute overactivation initiates arrhythmias, highlighting its role in triggered activity.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Calcineurin and CaMKII are calcium-dependent signaling molecules implicated in cardiac hypertrophy and arrhythmias.
  • CaMKII is also involved in the acute regulation of ion channels.

Purpose of the Study:

  • To investigate the roles of calcineurin and CaMKII in a canine model of compensated cardiac hypertrophy and a long QT syndrome phenotype.

Main Methods:

  • Atrioventricular (AV) block was induced in dogs to promote ventricular remodeling and susceptibility to dofetilide-induced torsades de pointes.
  • Cyclosporin A treatment reduced calcineurin activity but did not prevent remodeling or arrhythmias.
  • Western blotting assessed levels of phosphorylated CaMKII, phospholamban, Akt, and HDAC4.

Main Results:

  • Chronic AV block increased phosphorylation of Akt, CaMKII, and phospholamban, but not HDAC4.
  • Dofetilide induced torsades de pointes and early afterdepolarizations, with increased intracellular calcium and CaMKII autophosphorylation.
  • Pharmacological inhibition of CaMKII (W-7 and KN-93) counteracted these effects.

Conclusions:

  • The calcineurin pathway does not appear to contribute to long-term cardiac remodeling in this chronic AV block model.
  • Chronic CaMKII activation does not lead to HDAC4 phosphorylation, but acute CaMKII overactivation triggers arrhythmias via triggered activity.

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...